My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

35.25 +0.52 (+1.50%)

Streaming Delayed Price Updated: 3:06 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗

March 01, 2023

Via Benzinga

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

February 28, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics's Return On Capital Employed Overview ↗

February 28, 2023

Via Benzinga

Why Travere Therapeutics Stock Bolted Higher This Week ↗

February 23, 2023

A high-value regulatory approval lit a fire underneath the biotech's shares this week.

Via The Motley Fool

Travere Therapeutics's Earnings Outlook ↗

February 22, 2023

Via Benzinga

Travere Therapeutics Announces Proposed Public Offering of Common Stock

February 27, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

What 10 Analyst Ratings Have To Say About Travere Therapeutics ↗

February 22, 2023

Via Benzinga

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 21, 2023

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 21, 2023

Via Benzinga

Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday ↗

February 21, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

The Latest Analyst Ratings for Travere Therapeutics ↗

January 30, 2023

Via Benzinga

4 Analysts Have This to Say About Travere Therapeutics ↗

December 05, 2022

Via Benzinga

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗

February 21, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 20, 2023

Via Benzinga

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 17, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 17, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

February 16, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

February 08, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February ↗

February 01, 2023

These two growth stocks might deliver enormous gains for shareholders this month.

Via The Motley Fool

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2023 Outlook

January 09, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 14, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

December 12, 2022

Monday saw 196 companies set new 52-week lows.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.